Carl M. Gay, MD, PhD

Peer-Reviewed Articles

1. Ramkumar K, Stewart CA, Cargill KR, Della Corte CM, Wang Q, Shen L, Diao L, Cardnell RJ, Peng DH, Rodriguez BL, Fan YH, Heymach JV, Wang J, Gay CM, Gibbons DL, Byers LA. AXL Inhibition Induces DNA Damage and Replication Stress in Non-small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Mol Cancer Res 19(3):485-497, 2021. e-Pub 2020. PMID: 33172976.
2. Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC with Distinct Therapeutic Vulnerabilities. Cancer Cell 39(20):S1535-S6108, 2021. e-Pub 2021. PMID: 33482121.
3. Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao Z. Toxicity and Survival after Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol 16(2):269-277, 2021. e-Pub 2020. PMID: 33198942.
4. Zhou N, Bott M, Park BJ, Vallières E, Wilshire CL, Yasufuku K, Spicer JD, Jones DR, Sepesi B; Small Cell Lung Cancer Working Group (including Gay CM). Predictors of Survival following Surgical Resection of Limited-stage Small Cell Lung Cancer. J Thorac Cardiovasc Surg. e-Pub 2020.
5. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
6. Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. e-Pub 2020. PMID: 32608142.
7. Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Wistuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. STING Pathway Expression Identifies Non-small Cell Lung Cancers with an Immune-responsive Phenotype. J Thorac Oncol 15(5):777-791, 2020. e-Pub 2020. PMID: 32068166.
8. Gay CM, Parseghian CM, Byers LA. This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant Clones. Cancer Cell 37(1):5-7, 2020. PMID: 31951562.
9. Wang Y, Zheng Q, Jia B, An T, Zhao J, Wu M, Zhuo M, Li J, Zhong J, Chen H, Yang X, Chi Y, Dong Z, Sepesi B, Zhang J, Gay CM, Wang Z. Effects of Surgery on Survival of Early-Stage Patients with SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. Front Oncol 10:626, 2020. e-Pub 2020. PMID: 32391280.
10. Stewart CA, Gay CM, Xi Y, et al. Single-cell Analyses Reveal Increased Intratumoral Heterogeneity after the Onset of Therapeutic Resistance in Small-cell Lung Cancer. Nature Cancer 1:423-436, 2020.
11. Sen T, Della Corte CM, Milutinovic S, Cardnell RJ, Diao L, Ramkumar K, Gay CM, Stewart CA, Fan Y, Shen L, Hansen RJ, Strouse B, Hedrick MP, Hassig CA, Heymach JV, Wang J, Byers LA. Combination Treatment of the Oral CHK1 Inhibitor, SRA737 and Low Dose Gemcitabine, Enhances the Effect of PD-L1 Blockade by Modulating the Immune Microenvironment in Small Cell Lung Cancer. J Thorac Oncol 14(12):2152-2163, 2019. e-Pub 2019. PMID: 31470128.
12. Gay CM, Tong P, Cardnell RJ, Sen T, Su X, Ma J, Bara RO, Johnson FM, Wakefield C, Heymach JV, Wang J, Byers LA. Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. Clin Cancer Res 25(1):346-357, 2019. e-Pub 2018. PMID: 30257981.
13. Carretero-Ortega J, Chhangawala Z, Hunt S, Narvaez C, Menendez-Gonzalez J, Gay CM, Zygmunt T, Li X, Torres-Vasquez J. GIPC Proteins Negative Modulate Plexind1 Signaling during Vascular Development. Elife 3(8), 2019.
14. Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov 8(12):1548-1565, 2018. e-Pub 2018. PMID: 30322867.
15. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 8(9):1156-1175, 2018. e-Pub 2018. PMID: 30012853.
16. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK, Cancer Genome Atlas Research Network, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep 23(1):194-212.e6, 2018. PMID: 29617660.
17. Stewart AC, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA. Dynamic Variations in Epithelial-to-mesenchymal Transition (EMT), ATM, and SLFN11 Govern Response to PARP Inhibitors and Cisplatin in Small Cell Lung Cancer. Oncotarget 8(17):28575-28587, 2017. PMID: 28212573.
18. Abeshouse A, Adebamowo C, Gay CM, et al. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171(4):950-965, 2017.
19. Zygmunt T, Gay CM, Blondelle J, Singh MK, Flaherty KM, Means PC, Herwig L, Krudewig A, Belting HG, Affolter M, Epstein JA, Torres-Vazquez J. Semaphorin-PlexinD1 Signaling Limits Angiogenic Potential via the VEGF Decoy Receptor sFlt1. Dev Cell 21(2):301-314, 2011.

Invited Articles

1. Gay CM, Byers LA. PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?. J Thorac Oncol 14(8):1323-1326, 2019. PMID: 31345330.
2. Pilié PG, Gay CM, Byers LA, O'Connor MJ, Yap TA. PARP Inhibitors: Extending Benefit beyond BRCA-Mutant Cancers. Clin Cancer Res 25(13):3759-3771, 2019. e-Pub 2019. PMID: 30760478.
3. Della Corte CM, Gay CM, Byers LA. Beyond Chemotherapy: Emerging Biomarkers and Therapies as Small Cell Lung Cancer enters the Immune Checkpoint Era. Cancer 125(4):496-498, 2019. e-Pub 2019. PMID: 30620399.
4. Sen T, Gay CM, Byers LA. Targeting DNA Damage Repair in Small Cell Lung Cancer and the Biomarker Landscape. Transl Lung Cancer Res 7(1):50-68, 2018. PMID: 29535912.
5. Gay CM, Balaji K, Byers LA. Giving AXL the Axe: Targeting AXL in Human Malignancy. Br J Cancer 116(4):415-423, 2017. e-Pub 2017. PMID: 28072762.
6. Gay CM, Zygmunt T, Torres-Vazquez J. Diverse Functions for the Semaphorin Receptor PlexinD1 in Development and Disease. Dev Biol 349(1):1-19, 2011.

Other Articles

1. Gay CM, de Groot PM, Pietanza CM, Byers LA Durable, Exceptional Response to Temozolomide in a Patient with Extensive-stage Small Cell Lung Cancer (ES-SCLC) Metastatic to Brain. Cancer Treat Commun 10:17-20, 2017.
2. Gay CM, William WN, Wang SA, Oo TH Thymoma Complicated by Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia. J Natl Compr Canc Netw 12(11):1505-9, 2014. PMID: 25361796.

Editorials

1. Della Corte CM, Gay CM, Byers LA, Morgillo F. ILK and SHP2 Expression Identify a Poor Prognostic Cohort of EGFR-mutant Lung Cancer. EBioMedicine 39:5-6, 2019. PMID: 30553753.